KPV

KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-MSH, the 13-amino acid neuropeptide that functions as a key anti-inflammatory mediator in the melanocortin system. The discovery that this C-terminal tripeptide retains most of α-MSH's anti-inflammatory activity while being metabolically more stable has made KPV a subject of significant research interest.

KPV exerts anti-inflammatory effects through multiple pathways: inhibition of NF-κB activation, reduction of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), and modulation of macrophage polarization. These effects have been demonstrated in models of intestinal inflammation (IBD/colitis models), skin inflammation, and systemic inflammatory conditions. KPV has shown efficacy when delivered orally in some studies, which interests researchers studying gut-specific peptide delivery.

The compound's small size, simple tripeptide structure, and metabolic stability make it a practical research tool. At 50mg per vial, it is available in sufficient quantity for cell culture experiments, animal model studies, and formulation research targeting inflammatory pathways.